Christopher Haqq
2023 - Elicio Therapeutics
In 2023, Christopher Haqq earned a total compensation of $673.8K as Executive Vice President, Head of Research and Development and Chief Medical Officer at Elicio Therapeutics, a 42% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $185,545 |
|---|---|
| Salary | $488,276 |
| Total | $673,821 |
Haqq received $488.3K in salary, accounting for 72% of the total pay in 2023.
Haqq also received $185.5K in non-equity incentive plan.
Rankings
In 2023, Christopher Haqq's compensation ranked 1,568th out of 2,647 executives tracked by ExecPay. In other words, Haqq earned more than 40.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 1,568 out of 2,647 | 41st |
Division Manufacturing | 916 out of 1,447 | 37th |
Major group Chemicals And Allied Products | 582 out of 817 | 29th |
Industry group Drugs | 566 out of 783 | 28th |
Industry Pharmaceutical Preparations | 394 out of 555 | 29th |
Source: SEC filing on September 27, 2024.
Haqq's colleagues
We found four more compensation records of executives who worked with Christopher Haqq at Elicio Therapeutics in 2023.